Literature DB >> 26320367

Down-regulation of MicroRNA-381 promotes cell proliferation and invasion in colon cancer through up-regulation of LRH-1.

Yan Liang1, Qun Zhao1, Liqiao Fan1, Zhidong Zhang1, Bibo Tan1, Yu Liu1, Yong Li2.   

Abstract

The expression and roles of MicroRNA-381 (miR-381) has been explored in several types of human cancers. However, its biological functions in colon cancer remain largely unknown. Quantitative real-time PCR assays were used to detect the expression of miR-381 in human colon cancer tissues and adjacent normal tissues. miR-381 antisense oligos and mimics were introduced into SW480 and HCT116 cells. Bioinformatic prediction analysis was performed to identify the potential targets of miR-381. Protein expression analysis, luciferase assays and rescue assays were used to confirm the substrate of miR-381. We found that miR-381 was significantly down-regulated in human colon cancer tissues, compared with adjacent normal tissues. Introduction of miR-381 antisense oligos into SW480 and HCT116 cells promoted cell proliferation and invasion. Besides, inhibition of miR-381 could also support tumor growth in the nude mice. Additionally, bioinformatic prediction suggested that the nuclear receptor liver receptor homologue 1 (LRH-1) is a target gene of miR-381. Thus, our data suggested that down-regulation of miR-381 plays an important role in the colon cancer progression.
Copyright © 2015. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Colon cancer; LRH-1; MicroRNA; miR-381

Mesh:

Substances:

Year:  2015        PMID: 26320367     DOI: 10.1016/j.biopha.2015.07.020

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  21 in total

1.  MicroRNA-381 suppresses proliferation and invasion of prostate cancer cells through downregulation of the androgen receptor.

Authors:  Xin Rui; Ting-Ting Gu; Hua-Feng Pan; Si-Liang Shao; Hong-Xiang Shao
Journal:  Oncol Lett       Date:  2019-06-12       Impact factor: 2.967

2.  MicroRNA-381 protects myocardial cell function in children and mice with viral myocarditis via targeting cyclooxygenase-2 expression.

Authors:  Yong Zhang; Lingli Sun; Hui Sun; Zhongqin Yu; Xia Liu; Xia Luo; Cuifang Li; Dongming Sun; Tao Li
Journal:  Exp Ther Med       Date:  2018-04-20       Impact factor: 2.447

3.  MiR-381 inhibits migration and invasion in human gastric carcinoma through downregulatedting SOX4.

Authors:  Mingming Zhang; Shishu Huang; Dan Long
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

4.  miR-381-3p suppresses the proliferation of oral squamous cell carcinoma cells by directly targeting FGFR2.

Authors:  Xiao Yang; Huibing Ruan; Xi Hu; Anyi Cao; Li Song
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

5.  MicroRNA-381 regulates the occurrence and immune responses of coronary atherosclerosis via cyclooxygenase-2.

Authors:  Kaiyou Song; Lianting Li; Guiling Sun; Yanjin Wei
Journal:  Exp Ther Med       Date:  2018-03-12       Impact factor: 2.447

6.  Expression and role of VEGFA and miR-381 in portal vein tumor thrombi in patients with hepatocellular carcinoma.

Authors:  Jing Wang; Shuzhi Wu; Tianren Huang
Journal:  Exp Ther Med       Date:  2018-05-03       Impact factor: 2.447

7.  MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression.

Authors:  Bairong Xia; Huiyan Li; Shanshan Yang; Tianbo Liu; Ge Lou
Journal:  Tumour Biol       Date:  2016-01-14

8.  Downregulation of microRNA-30d promotes cell proliferation and invasion by targeting LRH-1 in colorectal carcinoma.

Authors:  Likun Yan; Jian Qiu; Jianfeng Yao
Journal:  Int J Mol Med       Date:  2017-04-20       Impact factor: 4.101

Review 9.  Potential roles of microRNAs and ROS in colorectal cancer: diagnostic biomarkers and therapeutic targets.

Authors:  Jingmei Lin; Chia-Chen Chuang; Li Zuo
Journal:  Oncotarget       Date:  2017-03-07

10.  MiR-381 functions as a tumor suppressor in colorectal cancer by targeting Twist1.

Authors:  Xinxin He; Yangnian Wei; Yong Wang; Ling Liu; Wen Wang; Nianfeng Li
Journal:  Onco Targets Ther       Date:  2016-03-07       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.